Toboroz
An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS
NCT07665437· 3. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Toboroz
Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors
NCT07660055· 1. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Fut, nem toboroz
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
NCT07468071· 1/2. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer
NCT07570979· 1. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Fut, nem toboroz
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
NCT07517263· 3. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
NCT07354074· 2. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Toboroz
A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction
NCT07465653· 1. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Toboroz
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
NCT07190300· 1/2. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Toboroz
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
NCT07261631· 1. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Toboroz
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
NCT07225504· 3. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Toboroz
A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation
NCT07217067· 2. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Toboroz
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
NCT07006727· 1. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Fut, nem toboroz
Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes
NCT07102628· 3. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
A First in Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of EDK060 in Adults With CMT1A.
NCT07140614· 1. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Fut, nem toboroz
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
NCT06991556· 2. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT07047118· 2. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
NCT06846281· 3. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Toboroz
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
NCT06784752· 3. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Toboroz
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
NCT06947993· 2. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Toboroz
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
NCT06726148· 1/2. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Fut, nem toboroz
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
NCT06840392· 3. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
Modifying PEST for Psoriatic Arthritis Screening
NCT06382051· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Toboroz
ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS
NCT06733922· 4. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Fut, nem toboroz
A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)
NCT06643481· 2. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
NCT06562192· 1. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Fut, nem toboroz
A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.
NCT06247995· 1/2. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Iptacopan in Patients With ANCA Associated Vasculitis
NCT06388941· 2. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
NCT05939414· 3. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Toboroz
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
NCT05646381· 2. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Fut, nem toboroz
A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC
NCT05849298· 2. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT
NCT05983198· 1. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma
NCT05888493· 3. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
NCT05803941· 4. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Fut, nem toboroz
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up
NCT05677451· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
A Study of Zigakibart in Adults With IgA Nephropathy
NCT05852938· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials
NCT05335876· 3. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
Asciminib Roll-over Study
NCT04877522· 4. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Fut, nem toboroz
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
NCT05126277· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
NCT05142696· 1/2. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events
NCT05360446· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
NCT05156281· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease
NCT05030428· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors
NCT04857372· 1. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis
NCT04926818· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
NCT04720157· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
NCT04699188· 1/2. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Pediatric Long-Term Follow-up and Rollover Study
NCT03975829· 4. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients
NCT03814746· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients
NCT03876769· 2. fázis· Novartis Pharmaceuticals· Forrás
Showing 50 of 51.